Prior research has identified key therapeutic targets (i.e., AKT1, TNF, IL-6, CASP3, and TP53) of this compound in ITP by integrating HPLC-based qualitative and quantitative analyses with network pharmacology and molecular docking. The gene discussed is TNF; the disease is autoimmune thrombocytopenic purpura.